By: Benzinga
Morgan Stanley Reiterates Equal-Weight Rating on Valeant Pharmaceuticals International on Obagi Acquisition
In a report published Wednesday, Morgan Stanley analyst David Risinger reiterated an Equal-Weight rating on Valeant Pharmaceuticals International (NYSE: VRX ). In the report, Risinger noted, “Valeant is set to acquire topical aesthetics company, Obagi, for $360M (1% of VRX EV). The proposed acquisition of Obagi Medical Products will extend
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here